Cell and gene therapy

Virus-like particles
#Biopharmaceuticals #Cell and gene therapy #Collaboration #Gene delivery #Gene therapy #Partnership #Vector BioPharma

Vector and iBET collaborate to accelerate gene delivery platform

Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform.  Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins.  Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading… Read More

#Business & Investment #News

Blood in a Petri dish
#BioMarin Pharmaceuticals #Cell and gene therapy #Gene therapy #Haemophilia #Orphan drugs #Phase III trial

Haemophilia one-time gene therapy effective for three years

An investigational one-time gene therapy for the treatment of adults with severe haemophilia A has been proven to be effective for more than three years from treatment.  BioMarin Pharmaceutical revealed the positive results from its ongoing global Phase III GENEr8-1 study of Roctavian (valoctocogene roxaparvovec).  … Read More

#News #Trending News

CAR-T cells attack cancer cells
#Cancer research #CAR-T #Cell and gene therapy #Cell therapy #High throughput screening #Immunotherapy #T cell activation

Watch now: Improve cell therapies with high-throughput CAR libraries

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this new on-demand… Read More

Webinar date:
Brought to you by Twist Bioscience
#Editor's Choice #News

CAR-T cells attack cancer cells
#Cancer research #CAR-T #Cell and gene therapy #Cell therapy #High throughput screening #Immunotherapy #T cell activation

Improving cell therapies with high-throughput CAR libraries

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron… Read More

Webinar date:
Brought to you by Twist Bioscience
#Webinars

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

AAV gene therapy
#AAV #Animal models #CANbridge Pharmaceuticals #Cell and gene therapy #China #Gene therapy #License agreement #Muscular dystrophy

Chinese biotech company consolidates gene therapy portfolio

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School.  Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along… Read More

#News

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

GenScript facility
#Biomanufacturing #Cell and gene therapy #Expansion #GenScript #Manufacturing

GenScript expands capacity for cell and gene therapy programmes

GenScript USA has expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies.  The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials. The company’s… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment of appropriate adults… Read More

#News #Regulatory #Trending News

Cancer cells
#Acute Myeloid Leukaemia #Cancer research #Cell and gene therapy #Clinical trials #Gene editing

First AML patient successfully transplanted with investigational drug 

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML).   The data observed from the first treated patient support the… Read More

#Cancer Research #News

CRISPR gene editing
#Cell and gene therapy #CRISPR #DNA #Gene editing #Genetics / genomics

Delivering on the promise of gene editing

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced… Read More

#Exclusive Content

Cell and gene therapy
#Cell and gene therapy #Contract Research Organisations (CROs)

CRO opens dedicated cell and gene therapy centre

Clinical research organisation (CRO) Emmes has unveiled a dedicated centre to expand its cell and gene therapy research.  The new centre will offer research services in clinical trial operations, study leadership, statistical services, data management, and pharmacovigilance.  Adam Mendizabal has been named the scientific leader… Read More

#News

#AAV #Cell and gene therapy #Gene therapy

Accelerating gene therapy research with AAV detection kits 

PerkinElmer has launched ready-to-use adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of serious diseases.   The validated and fully automatable assays are built on PerkinElmer’s AlphaLISA technology which requires no separation and are optimised, no-wash AAV detection assays. Read More

#News

#Cell and gene therapy #Collaboration #Drug delivery #Drug discovery

Partnership hopes to improve large-scale exosome production

Bio-chromatography company Sartorius BIA Separations (BIA) and exosomes medicines company Exopharm have signed a Material Transfer Agreement and associated collaborative programme.  The partnership aims to combine Exopharm’s LEAP technology together with BIA’s CIM (Convective Interaction Media) monolith chromatography for improved large-scale therapeutic exosome production and commercialisation.  The companies hope to… Read More

#Business & Investment #News

Cell culture media
#Biologics #Bioproduction #Cell and gene therapy #Cell therapy #Life sciences #Manufacturing

Fujifilm expands cell culture media manufacturing

Fujifilm Corporation has announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.  The new site will be operated by Fujifilm Irvine Scientific, a manufacturer of cell culture solutions for life science research, bioproduction, cell therapy… Read More

#News